Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05213052 · ClinicalTrials.gov registry record · NA
Effects of Topical Cream for Pain Relief
A NA study, sponsored by Natural Immune Systems.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT05213052: Completed NA study, sponsored by Natural Immune Systems.
NCT05213052 is a NA study that has completed, run by Natural Immune Systems. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05213052, a NA study, has completed, sponsored by Natural Immune Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
To perform a clinical proof-of-concept study on a novel topical formula for pain relief.
Primary Outcome
Pain questionnaire - yes/no, score 0-24 hours
Interventions
- OTHER Topical cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2022-05-01 |
| Phase | NA |
What the finished NCT05213052 record still lists
NCT05213052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Topical cream is the first listed.
NCT05213052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05213052 about?
NCT05213052 is a clinical study titled "Effects of Topical Cream for Pain Relief". To perform a clinical proof-of-concept study on a novel topical formula for pain relief.
What is the current status of trial NCT05213052?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2021-08-01. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT05213052?
The interventions under investigation include: Topical cream (OTHER).
Who is sponsoring clinical trial NCT05213052?
This trial is sponsored by Natural Immune Systems, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05213052's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI